Table 4.
Association of age, sex, HIV disease stage, lipodystrophy and HAART with the metabolic syndrome
| Patients with MS | Patients without MS | p-value | |
|---|---|---|---|
| Number (%) | 27 (15.6) | 146 (84.4) | |
| Mean age in yrs. (SD) | 44.9 (11.2) | 37.5 (11.5) | 0.001* |
| Sex (%) | |||
| Male | 2 (7.4) | 37 (25.3) | 0.040* |
| Female | 25 (92.6) | 109 (74.7) | |
| Mean BMI in kg/m 2 (SD) | 25.2 (3.4) | 23.7 (4.0) | 0.002* |
| HIV disease stage (%) | |||
| Primary | 20 (74.1) | 86 (58.9) | 0.123 |
| Stage 1 | 3 (11.1) | 44 (30.1) | |
| Stage 2 | 4 (14.8) | 16 (11) | |
| Mean CD4 cell count in cells/μL (SD) | 412.4 (173.6) | 348.2 (202.1) | 0.248 |
| Mean waist circumference in cm (SD) | 94.37 (6.9) | 85.11 (7.7) | 0.001* |
| Mean HDL-C in mg/dL (SD) | 37.7 (11.9) | 48.6 (17.5) | 0.043* |
| Mean FBS in mg/dL (SD) | 111.6 (13.0) | 91.4 (20.4) | 0.001* |
| Mean triglyceride in mg/dL (SD) | 125.5 (73.0) | 83.7 (40.4) | 0.014* |
| Antiretroviral therapy exposure | |||
| Naïve-ART (%) | 7 (25.9) | 54 (37) | 0.065 |
| Never on protease inhibitor (%) | 15 (55.6) | 47 (32.2) | |
| Currently protease inhibitor (%) | 5 (18.5) | 45 (30.8) | |
| Mean years of HIV infection duration (SD) | 3.6 (1.1) | 2.7 (0.8) | 0.242 |
| Mean years of HAART duration (SD) | 2.4 (0.7) | 1.9 (0.3) | 0.148 |
*Statistically significant.